elagolix (orilissa) Report issue

Small molecule Approved FDA Priority Review FDA
AACT ChEMBL DrugBank Drugs@FDA MeSH PubChem

Active Ingredient History

NOW
  • Now
Elagolix (ABT-620) is an oral gonadotropin-releasing hormone antagonist being studied for the treatment of endometriosis and uterine fibroids. The U.S. Food and Drug Administration (FDA) approved AbbVie's elagolix under the brand name Orilissa as the first and only oral gonadotropin-releasing hormone (GnRH) antagonist specifically developed for women with moderate to severe endometriosis pain.   NCATS

Chemistry

  • SMILES: COc1cccc(C2=C(C)N(Cc3c(F)cccc3C(F)(F)F)C(=O)N(C[C@H](NCCCC(=O)O)c4ccccc4)C2=O)c1F
  • InChIKey: HEAUOKZIVMZVQL-VWLOTQADSA-N
  • Mol. Mass: 631.6
  • ALogP: 5.54
  • ChEMBL Molecules:
    elagolix  
    elagolix sodium  
More Chemistry

Pharmacology

Drug Pricing (per unit)

United States

$16.7310 - $176.4525
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

elagolix | elagolix sodium | nbi-56418 | nbi-56418-na | obe2109 | r-(+)-4-(2-(5-(2-fluoro-3-methoxyphenyl)-3-(2-fluoro-6-(trifluoromethyl)benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2h-pyrimidin-1-yl)-1-phenylethylamino)butyrate

Organizations (17)

Research & Development (17)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (10)

Approved Indications (1)


 

Endometriosis (approved 2018)

Experimental Indications - Clinical Trial Phases 1-4 (10)


 

Cortisone (Phase 4)

Endometriosis (Phase 3)

Infertility (Phase 3)

Leiomyoma (Phase 3)

Menorrhagia (Phase 3)

Ovarian Diseases (Phase 1)

Ovulation (Phase 4)

Pain (Phase 2)

Polycystic Ovary Syndrome (Phase 2)

Uterine Diseases (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 31
  • # of Trial Organizations: 17

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue